Pacira BioSciences Inc. (NASDAQ:PCRX) is one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds.
On March 2, Pacira BioSciences Inc. (NASDAQ:PCRX) presented data from its IGOR registry at the American Academy of Orthopedic Surgeons (AAOS) 2026 Annual Meeting. The company highlighted that Exparel was associated with improved pain outcomes, reduced opioid use, and shorter hospital stays compared to standard treatments.
Pressmaster/Shutterstock.com
The company also noted that iovera demonstrated longer-lasting pain relief and functional improvement, with benefits extending up to 12 months. The findings support the company’s growing presence in post-surgical pain management solutions.
On February 12, Pacira BioSciences Inc. (NASDAQ:PCRX) brought to attention the new survey results that have been released by the Voices for Non-Opioid Choices coalition. The results reflect the response to the first year of implementation of the Non-Opioids Prevent Addiction, NOPAIN, Act. This was done by conducting a national awareness campaign, trials, and usage survey of nearly 750 hospital and health system directors of pharmacy, medical directors, surgeons, and anaesthesiologists within ambulatory surgery centres.
The results of this survey show the beginning impact of the NOPAIN Act. This act was implemented on January 1, 2025, and the results concluded that 85 percent of facility representatives surveyed were aware of the legislation. In addition, more than half of the facilities surveyed have implemented changes to increase the utilization of qualifying non-opioid options. Over 80 percent of those surveyed have seen a reduction in opioid prescribing for immediate post-surgery and discharge due to the legislation.
Pacira BioSciences Inc. (NASDAQ:PCRX) is focused on the development and marketing of non-opioid pain management and regenerative health solutions to medical practitioners. Its portfolio includes EXPAREL, ZILRETTA, PCRX-201, NOCITA, and a handheld cryoanalgesia device.
While we acknowledge the risk and potential of PCRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PCRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
